What is Bluepha?
Founded in 2016, Bluepha is a synthetic biology enterprise headquartered in Beijing that specializes in the development of cost-effective, sustainable bioplastics. The company operates at the intersection of biotechnology and material science, utilizing advanced microbial fermentation processes to create high-performance, biodegradable alternatives to conventional petroleum-based plastics. By optimizing metabolic pathways, Bluepha has established a competitive edge in the bio-manufacturing landscape, aiming to disrupt the traditional plastics industry with scalable, environmentally friendly solutions that meet the rigorous demands of modern enterprise-level applications.
How much funding has Bluepha raised?
Bluepha has raised a total of $72.3M across 2 funding rounds:
Series A
$6M
Series B
$66.3M
Series A (2019): $6M with participation from Zhongguancun Development Start Fund, Zhongguancun Development Frontier Fund, and Shenzhen Qianhai Fof
Series B (2021): $66.3M led by Qianhai FOF, Taihecap, FreeS Fund, GL Ventures, China Renaissance Holdings, Qihang Capital, Trinity Innovation Fund, Lightspeed Venture Partners, Fangyuan Capital, Fujian Septwolves Industry Co., and Country Garden
Key Investors in Bluepha
Taihecap
Taihecap is a leading industrial capital management group in China that provides comprehensive capital services to enterprise clients by leveraging deep industry insights and rich resources.
Lightspeed Venture Partners
Lightspeed Venture Partners is a global multistage venture capital firm that invests in early and growth-stage technology companies across sectors such as enterprise software, consumer, and infrastructure.
FreeS Fund
FreeS Fund is a venture capital firm based in Beijing, China, that focuses on providing financial support to early-stage and early growth-stage startups.
What's next for Bluepha?
Looking ahead, Bluepha is poised to leverage its recent capital infusion to expand its manufacturing infrastructure and enhance its R&D pipeline. The strategic focus will likely center on optimizing production efficiency to achieve price parity with traditional plastics, a critical milestone for widespread market adoption. Furthermore, the company is expected to deepen its collaborations with industrial partners to integrate its bioplastic solutions into global supply chains. As the regulatory environment increasingly favors sustainable materials, Bluepha's ability to scale its proprietary technology will be the primary driver of its long-term value creation and market leadership in the synthetic biology sector.
See full Bluepha company page
